Drug Cos. Want Blue Cross Unit Sanctioned In Aggrenox MDL

Law360 (February 28, 2018, 6:04 PM EST) -- Boehringer Ingelheim and Teva have asked a Connecticut federal court to sanction Blue Cross and Blue Shield of Louisiana for allegedly dodging discovery in multidistrict litigation in which it’s accusing the drugmakers of entering into a $120 million pay-for-delay deal aimed at blocking generic versions of the stroke-prevention medication Aggrenox.

BCBSLA has repeatedly missed discovery deadlines and didn’t communicate about any issues during that time, and then dumped a still-incomplete but large trove of documents on the drug companies last-minute attached to a deficient privilege log,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.